Literature DB >> 17562654

Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.

A L Sérandour1, N Tsapis, C Gervelas, G Grillon, M Fréchou, J R Deverre, H Bénech, E Fattal, P Fritsch, J L Poncy.   

Abstract

This study evaluates the decorporation efficacy of a pulmonary administration of a new Ca-DTPA (diethylenetriaminepentaacetic acid) dry powder (18 micromol kg(-1) of body mass) after pulmonary contamination of rats with different Pu compounds. After inhalation of PuO2, a delayed intratracheal administration of DTPA cannot reduce significantly the retention of Pu in the lungs but limits its transfer in liver and skeleton. After pulmonary contamination by Pu nitrate, early insufflation of the DTPA powder appears twice as more efficient than an i.v injection of DTPA (30 micromol kg(-1)) to reduce Pu retention in the lungs and is as effective as i.v. injection to limit the extrapulmonary deposit. In contrast, a delayed administration of DTPA cannot reduce the lung or extrapulmonary retention. In conclusion, the improvement of aerodynamic properties of DTPA powder leads to an increase of DTPA amount deposited in the lungs and enhances the body decorporation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562654     DOI: 10.1093/rpd/ncm300

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  2 in total

1.  Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA): formulation design and optimization studies.

Authors:  Yu-Tsai Yang; Anthony J Di Pasqua; Yong Zhang; Katsuhiko Sueda; Michael Jay
Journal:  Pharm Dev Technol       Date:  2013-09-19       Impact factor: 3.133

2.  Comparison of Local and Systemic DTPA Treatment Efficacy According to Actinide Physicochemical Properties Following Lung or Wound Contamination in the Rat.

Authors:  Nina M Griffiths; Anne Van der Meeren; Olivier Grémy
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.